164 related articles for article (PubMed ID: 35999603)
1. Directing ricin-based immunotoxins with targeting affibodies and KDEL signal peptide to cancer cells effectively induces apoptosis and tumor suppression.
Park SG; Kim H; Jun H; Choi SY; Kim E; Kang S
J Nanobiotechnology; 2022 Aug; 20(1):387. PubMed ID: 35999603
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
Jiao P; Zhang J; Dong Y; Wei D; Ren Y
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
[TBL] [Abstract][Full Text] [Related]
3. Expression of ricin A chain and ricin A chain-KDEL in Escherichia coli.
Zhan J; Chen Y; Wang K; Zheng S
Protein Expr Purif; 2004 Apr; 34(2):197-201. PubMed ID: 15003251
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of KDEL-terminated ricin toxins correlates with distribution of the KDEL receptor in the Golgi.
Tagge E; Chandler J; Tang BL; Hong W; Willingham MC; Frankel A
J Histochem Cytochem; 1996 Feb; 44(2):159-65. PubMed ID: 8609372
[TBL] [Abstract][Full Text] [Related]
5. Addition of an endoplasmic reticulum retrieval sequence to ricin A chain significantly increases its cytotoxicity to mammalian cells.
Wales R; Roberts LM; Lord JM
J Biol Chem; 1993 Nov; 268(32):23986-90. PubMed ID: 8226941
[TBL] [Abstract][Full Text] [Related]
6. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
Kornfeld SB; Leonard JE; Mullen MD; Taetle R
Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
[TBL] [Abstract][Full Text] [Related]
7. Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation.
Zhan J; Stayton P; Press OW
Cancer Immunol Immunother; 1998 Mar; 46(1):55-60. PubMed ID: 9520293
[TBL] [Abstract][Full Text] [Related]
8. Adapting yeast as model to study ricin toxin a uptake and trafficking.
Becker B; Schmitt MJ
Toxins (Basel); 2011 Jul; 3(7):834-47. PubMed ID: 22069743
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
11. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
[TBL] [Abstract][Full Text] [Related]
12. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage.
Baluna R; Coleman E; Jones C; Ghetie V; Vitetta ES
Exp Cell Res; 2000 Aug; 258(2):417-24. PubMed ID: 10896793
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells.
Jaffrézou JP; Sikic BI; Laurent G
Blood; 1994 Jan; 83(2):482-9. PubMed ID: 7506953
[TBL] [Abstract][Full Text] [Related]
14. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
[TBL] [Abstract][Full Text] [Related]
15. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive effects of anti-transferrin receptor immunotoxin in a multicellular tumor spheroid model.
Chignola R; Foroni R; Candiani C; Franceschi A; Pasti M; Stevanoni G; Anselmi C; Tridente G; Colombatti M
Int J Cancer; 1994 Apr; 57(2):268-74. PubMed ID: 8157364
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor.
Vollmar AM; Banker DE; Mendelsohn J; Herschman HR
J Cell Physiol; 1987 Jun; 131(3):418-25. PubMed ID: 3496342
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma.
Hertler AA; Spitler LE; Frankel AE
Cancer Drug Deliv; 1987; 4(4):245-53. PubMed ID: 3502618
[TBL] [Abstract][Full Text] [Related]
19. Immunotoxins containing A-chain of mistletoe lectin I are more active than immunotoxins with ricin A-chain.
Tonevitsky AG; Agapov II; Shamshiev AT; Temyakov DE; Pohl P; Kirpichnikov MP
FEBS Lett; 1996 Aug; 392(2):166-8. PubMed ID: 8772196
[TBL] [Abstract][Full Text] [Related]
20. [Immuno-ricin A chain specific for gastric cancer: internalization and its significance].
Wang F
Zhonghua Yi Xue Za Zhi; 1992 Jul; 72(7):401-4, 445-6. PubMed ID: 1330228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
